1. Home
  2. REBN vs KALA Comparison

REBN vs KALA Comparison

Compare REBN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.26

Market Cap

11.5M

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.70

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
KALA
Founded
2015
2009
Country
United States
United States
Employees
N/A
6
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
13.3M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
REBN
KALA
Price
$1.26
$0.70
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
51.2K
56.8K
Earning Date
04-22-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
67.39
EPS
N/A
N/A
Revenue
$8,094,628.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.54
N/A
52 Week Low
$0.91
$0.07
52 Week High
$2.95
$20.58

Technical Indicators

Market Signals
Indicator
REBN
KALA
Relative Strength Index (RSI) 47.39 29.61
Support Level $1.20 $0.56
Resistance Level $2.02 $0.72
Average True Range (ATR) 0.12 0.12
MACD -0.00 0.01
Stochastic Oscillator 31.71 4.41

Price Performance

Historical Comparison
REBN
KALA

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: